Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer

Published:2013-11 Issue:2 Volume:131 Page:368-373
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Argenta Peter A.,Um Inhwa,Kay Charlene,Harrison David,Faratian Dana,Sueblinvong Thanasak,Geller Melissa A.,Langdon Simon P.

Funder

Scottish Funding Council

Charon fund

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference33 articles.

1. Cancer biomarkers: selecting the right drug for the right patient;Kelloff;Nat Rev Drug Discov,2012

2. Antiestrogen therapy is active in a selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients;Smyth;Clin Cancer Res,2007

3. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer;Argenta;Gynecol Oncol,2009

4. Contrasting effects of17h-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo;Langdon;Int J Cancer,1993

5. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines;Langdon;J Steroid Biochem Mol Biol,1994

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options;Biomedicines;2023-08-01

2. Decreased risk of ovarian cancer associated with rs9898876 sex hormone-binding globulin gene variant;Molecular Biology Reports;2022-03-11

3. GTW inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer via ILK/AKT/GSK3β/Slug Signalling Pathway;Journal of Cancer;2021

4. Lotus petal flap and vertical rectus abdominis myocutaneous flap in vulvoperineal reconstruction: a systematic review of differences in complications;Journal of Plastic Surgery and Hand Surgery;2020-10-15

5. Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer;Cancers;2020-06-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3